In recent years, accumulating evidence suggests that HDAC inhibitors, including valproic acid, butyric acid, and trichostatin A, exert neuroprotective effects in many neurological diseases, such as cerebral ischemia (Kim et al., 2007; Li et al., 2019) and spinal cord injury (Zhang S. et al., 2018). This evidence concerns the gene HDAC9 and Cerebral ischemia.